Results 41 to 50 of about 2,485 (155)

Approved HIV reverse transcriptase inhibitors in the past decade

Acta Pharmaceutica Sinica B, 2022
HIV reverse transcriptase (RT) inhibitors are the important components of highly active antiretroviral therapies (HAARTs) for anti-HIV treatment and pre-exposure prophylaxis in clinical practice.
Guangdi Li, Yali Wang, Erik De Clercq
doaj   +1 more source

Impact and experience of participant engagement activities in supporting dapivirine ring use among participants enrolled in the phase III MTN-020/ASPIRE study

BMC Public Health, 2021
Background Low adherence to investigational products can negatively impact study outcomes, limiting the ability to demonstrate efficacy. To continue advancing potential new HIV prevention technologies, efforts are needed to improve adherence among study ...
Morgan Garcia, Ellen Luecke, Ashley J. Mayo, Rachel Scheckter, Patrick Ndase, Flavia Matovu Kiweewa, Doreen Kemigisha, Petina Musara, Leila E. Mansoor, Nishanta Singh, Kubashni Woeber, Neetha S. Morar, Nitesha Jeenarain, Zakir Gaffoor, Daniel K. Gondwe, Yvonne Makala, Llewellyn Fleurs, Krishnaveni Reddy, Thesla Palanee-Phillips, Jared M. Baeten, Ariane van der Straten, Lydia Soto-Torres, Kristine Torjesen   +22 more
doaj   +1 more source

Extension into the entrance channel of HIV-1 reverse transcriptase—Crystallography and enhanced solubility [PDF]

, 2013
Non-nucleoside inhibitors of HIV-1 reverse transcriptase (HIV-RT) are reported that feature extension into the entrance channel near Glu138. Complexes of the parent anilinylpyrimidine 1 and the morpholinoethoxy analog 2j with HIV-RT have received ...
Anderson, Karen S., Arnold, Eddy, Bauman, Joseph D., Bollini, Mariela, Cisneros, José A., Das, Kalyan, Frey, Kathleen M., Jorgensen, William L., Spasov, Krasimir A.   +8 more
core   +1 more source

Single-domain antibodies and their formatting to combat viral infections [PDF]

, 2018
Since their discovery in the 1990s, single-domain antibodies (VHHs), also known as NanobodiesA (R), have changed the landscape of affinity reagents. The outstanding solubility, stability, and specificity of VHHs, as well as their small size, ease of ...
Ballegeer, Marlies, De Vlieger, Dorien, Rossey, Iebe, Saelens, Xavier, Schepens, Bert   +4 more
core   +2 more sources

Efficient regulatory approval of two novel HIV prevention interventions in a resource-limited setting: experiences from Zimbabwe

Frontiers in Reproductive Health, 2023
The global burden of HIV remains unacceptably high despite significant progress made in HIV treatment and prevention. There is an urgent need to scale up the comprehensive HIV prevention strategies that include pre-exposure prophylaxis (PrEP).
Caroline Murombedzi, Libert Chirinda, Gift T. Chareka, Z. Mike Chirenje, Nyaradzo M. Mgodi   +4 more
doaj   +1 more source

Female Genital Fibroblasts Diminish the In Vitro Efficacy of PrEP against HIV

Viruses, 2022
The efficacy of HIV pre-exposure prophylaxis (PrEP) is high in men who have sex with men, but much more variable in women, in a manner largely attributed to low adherence.
Ashley F. George, Matthew McGregor, David Gingrich, Jason Neidleman, Rebecca S. Marquez, Kyrlia C. Young, Kaavya L. Thanigaivelan, Warner C. Greene, Phyllis C. Tien, Amelia N. Deitchman, Trimble L. Spitzer, Nadia R. Roan   +11 more
doaj   +1 more source

Polymeric gels for intravaginal drug delivery [PDF]

, 2017
This document is the Accepted Manuscript version of the following article: Michael T. Cook, and Marc b. Brown, ‘Polymeric gels for intravaginal drug delivery’, Journal of Controlled Release, Vol. 270: 145-157, January 2018. Under embargo until 6 December
Brown, Marc, Cook, Michael
core   +2 more sources

The influence of social constructs of hegemonic masculinity and sexual behaviour on acceptability of vaginal microbicides in Zambia [PDF]

, 2017
Vaginal microbicides are heralded as a woman’s HIV prevention method. This ethnographic study, conducted in a trial setting in Zambia, explored how the social construction of masculinity and sexual behaviour influenced the acceptability of vaginal ...
Bond, V, Dixey, R, Mweemba, O, White, AK
core   +2 more sources

Pre-exposure prophylaxis (PrEP) in an era of stalled HIV prevention: Can it change the game? [PDF]

, 2018
Pre-exposure prophylaxis (PrEP) for HIV prevention has evolved significantly over the years where clinical trials have now demonstrated the efficacy of oral PrEP, and the field is scaling-up implementation.
Eakle, Robyn, Rees, Helen, Venter, Francois   +2 more
core   +1 more source

Planning for decentralized, simplified prEP: Learnings from potential end users in Ga-Rankuwa, gauteng, South Africa

Frontiers in Reproductive Health, 2023
BackgroundIn South Africa, youth experience challenges with oral Pre-Exposure Prophylaxis (PrEP) access and uptake. Taking services out of healthcare settings has the potential to increase reach and overcome these challenges.
Paballo Mataboge, Susan Nzenze, Nqaba Mthimkhulu, Mbali Mazibuko, Alison Kutywayo, Vusile Butler, Nicolette Naidoo, Saiqa Mullick   +7 more
doaj   +1 more source